Monday, December 30, 2013

Actinium Pharmaceuticals, Inc. (ATNM) Report Annual Shareholder Meeting’s Voting Results and Strong Participation

Actinium Pharmaceuticals, a biopharmaceutical company with a proprietary platform that combines the precision targeting of monoclonal antibodies with the killing power of alpha and beta radioisotopes, today reported the voting results from its annual general meeting of shareholders (the “meeting”) which was held last Monday.

Holders of approximately 80 percent, or 18.3 million, of Actinium Pharmaceuticals’ outstanding shares as of the record date November 7, 2013, participated in the voting at the meeting. According to today’s press release, all of the proposed resolutions were approved and ratified including Proposal 1 which showed unanimous support for the Board of Directors.

Commenting on the results of the meeting, Mr. Sandesh Seth, Chairman of the Board of Actinium Pharmaceuticals, stated, “We are thankful that our shareholders took the time to show their support for the Company and its Board of Directors by voting in such large numbers. We will strive to meet their expectations as we steer the Company from a strategic perspective and work with Management to assure implementation of these strategies as Actinium progresses its lead drug candidates Iomab™-B and Actimab-A in their planned Phase 3 and ongoing Phase 1/2 trials, respectively.”

Dr. Kaushik J. Dave, President and CEO of Actinium Pharmaceuticals, added, “We are pleased that so many of our shareholders were able to participate in the Company’s annual general meeting by casting their votes on these important proposals. We express our thanks to them in supporting further efforts by Actinium’s Board of Directors and its Management to continue implementing our given strategies to move the Company forward for the benefit of all stockholders.”

For more information on Actinium Pharmaceuticals, visit www.actiniumpharmaceuticals.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Methes Energies International Ltd. (MEIL) Closes a $2.1 Million Private Placement

Methes Energies International, a renewable energy company that uses its own proprietary technology to produce high-quality biodiesel processors and systems, today announced the completion of a $2.1 million private placement pursuant to Regulation D of the Securities Act of 1933, as amended. In the offering, Methes sold 1.1 million units to select institutional and accredited investors, each unit consisting of one share of common stock and one warrant. Each warrant is exercisable to purchase one share of common stock at $4.00 and expires five years from the date of issuance. Net proceeds from the offering were approximately $1.7 million, after deducting offering expenses and placement agent fees.

ViewTrade Securities, acted as the lead placement agent and Newbridge Securities Inc. acted as a co-placement agent.

Michel G. Laporte, Chairman & CEO of Methes Energies International Ltd., stated, “We are pleased to have finalized this private placement with ViewTrade. Our relationship with ViewTrade began when they acted as co-underwriters in our IPO and have been a good team to work with. This financing allows us to expand our production at Sombra by adding some equipment that will help us save money and be more efficient as well as strengthen our balance sheet. We are now in a better position to execute our plan which is to go to maximum production at Sombra by the end of the first quarter.”

For more information, please visit www.methes.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Jameson Stanford Resources Corp. (JMSN) Maintains Tight Focus on High Potential Properties in Utah

Jameson Stanford is engaged in the development of productive mining claims in the Western United States. Its current specific focus is on activities in connection with two high-grade copper, gold, silver, and base metals properties in Utah.

Located in the Star Mountain range of Beaver County, Utah, is the company’s Star Mountain project, which involves total area of 4,998 acres with borders expanding in accordance with exploration results. Star Mountain consists of 117 lode mining claims and four metalliferous mineral lease sections.

Ogden Bay Minerals is the company’s second area of interest. This developing mineral excavation project is located on federal protected wetlands, canals, and river systems in West Ogden, Utah. Here, large deposits of alluvial mineral deposits are created and replenished from 125 miles of river flow from the nearby Wasatch Mountain Range. Jameson Stanford believes it can extract gold, silver, silica, and other commercial metals and minerals in this area by using gravity separation methods.

In 2014, the company hopes to commence production and mining operations at a third project in Juab County, Utah. The company’s Spor Mountain project consists of nine lode mining claims and three metalliferous mineral lease sections involving a total area of 2,098 acres.

Continuing to strengthen and grow its portfolio, Jameson Stanford also seeks to identify and acquire under-developed mining claims and mineral leases that demonstrate significant unexploited production value.

For more information, visit www.jamesonstanford.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Friday, December 27, 2013

Pivotal Phase 3 Trial a Key Objective for Boston Therapeutics (BTHE) in 2014

Boston Therapeutics is a pharmaceutical company using complex carbohydrate chemistry to advance its PAZ320 and IPOXYN drug candidates for the treatment of Type 2 diabetes. With 2013 under wraps, BTHE looks to have an exciting first half of the upcoming year.

In mid-2014, BTHE hopes to start a pivotal phase 3 study of PAZ320, a chewable tablet to be taken before meals to reduce post-meal elevation of blood glucose in Type 2 diabetics by blocking the action of carbohydrate-hydrolyzing enzymes.

The two-year study, to be conducted in the U.S., Europe, Hong Kong, Korea, and China, will evaluate the effects of PAZ320 on glucose and hemoglobin A1c (HbA1c) in approximately 300 Type 2 patients currently taking metformin.

Thus far, Acarbose is the only drug that has been developed for the non-systemic environment to prevent glucose formation, though it is accompanied by side effects and limited functionality. BTHE’s goal is to develop a superior drug without the side effects.

An earlier phase 2 study of PAZ320 suggests that the company is on the right track in doing so. In the study, 21 patients treated with PAZ320 achieved a 40 percent reduction in post-meal blood glucose levels with no serious adverse events.

BTHE in November began enrolling patients in a phase 2b clinical study of PAZ320. A total of 24 patients currently being treated with metformin will receive PAZ320 in a double-blind, placebo-controlled study. The primary endpoint of the study is to evaluate the effect of PAZ320 compared to placebo to determine post-meal blood glucose levels after consumption of a test meal. The company plans to announce safety and glucose results during the first quarter of 2014.

For more information, visit www.bostonti.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

CytRx Corp. (CYTR) Featured on Forbes.com for Aldoxorubicin’s Potential as Treatment for Brain Cancer

In a recent review published on Forbes.com, contributor Tom Meyer highlights four biotech companies focused on advancing treatments for glioblastoma multiforme (GBM), listing CytRx Corp. alongside ImmunoCellular Therapeutics (IMUC), Northwest Biotherapeutics (NWBO), and Celldex Therapeutics (CLDX).

To read the full article visit: http://www.forbes.com/sites/tommeyer/2013/12/27/the-race-to-develop-a-brain-cancer-treatment-takes-an-interesting-turn/

GBM is the most aggressive malignant brain tumor in humans. Current treatment includes chemotherapy, radiation, and surgery, though median survival even with these extremes is only 15 months.

Investors for a season had high expectations that ImmunoCellular Therapeutics and Northwest Biotherapeutics would lead the pack in developing an effective treatment for GBM, but as Meyer explains in the article, both companies fell short of this achievement.

“They were among the first to get into the field and have made significant progress. Unfortunately, for ImmunoCellular, that dream came crashing down earlier this month. On December 11th, the company reported that their Phase II trial did not reach statistical significance in the primary outcome of overall survival. This was a serious blow to both investors and the medical community as many had been hoping that the company would file for accelerated approval if the results were extremely favorable. Shares of the company collapsed after the announcement and traded as low $0.65. … Unfortunately, it appears that Northwest Biotherapeutics may soon take an ill-fated journey to the land of failed trials.”

Alternately, Meyer discusses his bullish stance on CytRx, a biopharmaceutical R&D company focused on the clinical development of aldoxorubicin, the company’s improved version of widely used and highly toxic chemotherapeutic agent, doxorubicin.

CytRx recently reported positive data from its phase 2b trial in patients with soft tissue sarcomas, demonstrating aldoxorubicin’s superiority over doxorubicin in progression-free survival. The company in November said it was initiating a phase 2 clinical trial of aldoxorubicin in patients with GBM.

“Given the remarkable results that aldoxorubicin demonstrated in 1st-Line STS, it’s hard not to believe that something similar could be in store for the Phase 2 GBM trial. CytRx certainly appears poised for a significant run in the months and years ahead as the company’s platform continues to be validated by science.”

Meyer further emphasizes his outlook on CytRx, detailing the company’s strong cash balance, which is expected to fund operating expenses through 2015.

Celldex Therapeutics also gets a positive review for its brain cancer candidate rindopepimut, which is currently being evaluated in a phase 3 ACT IV study for newly diagnosed GBM, as well as in a phase 2 ReACT study in recurrent GBM.

Taking each company’s performance and potential into consideration, Meyer surmises that:

“Investors looking to allocate capital to a promising company in the brain cancer space should consider CytRx Corporation and Celldex Therapeutics. Both companies appear to be developing unique, innovative approaches for tackling a complex and deadly disease. On the flip side, investors should probably stay away from both ImmunoCellular Therapeutics and Northwest Biotherapeutics, both of whom appear to be pursuing a science that hasn’t quite proven itself.”

For more information, visit www.cytrx.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

FuelCell Energy, Inc. (FCEL) Reports Completion of 14.9 Megawatt Fuel Cell Park

FuelCell Energy, a global leader in the design, manufacture, operation, and service of efficient and reliable fuel cell power plants, announced the completion of the 14.9 megawatt (MW) Bridgeport fuel cell park and acceptance by Dominion, the project owner. The installation consists of five fuel cell power plants and an organic rankine cycle turbine for added output and further efficiency gains, with the power output adequate to power approximately 15,000 average size U.S. homes.

“Dominion is pleased to be adding 15 megawatts of additional renewable energy in Connecticut to our existing 2,100 megawatts of carbon-free power from our Millstone Power Station,” stated David A. Christian, Dominion Generation chief executive officer. “These stations are generating clean, reliable electricity for Connecticut.”

“The beginning of operations for the Bridgeport Fuel Cell Power Park represents an important milestone on the path toward Governor Malloy’s vision of a cheaper, cleaner, and more reliable energy future for Connecticut’s residents and businesses,” commented Connecticut Department of Energy and Environmental Protection Commissioner Daniel Esty. “This project highlights Connecticut’s new approach to clean energy, which focuses on using limited ratepayer dollars to leverage private capital and to get the greatest possible ratepayer benefit per dollar of public funds expended.”

“The commencement of commercial operation by delivering electricity to the electric grid is a major milestone for a Project that is bringing international recognition to the City of Bridgeport and highlighting the capability of utility-scale fuel cell parks,” added Bridgeport Connecticut Mayor Bill Finch. “This event marks the completion of a unique and successful public/private development effort, and the delivery of electricity is a key element of the City’s BGreen 2020 initiative as we work to make Bridgeport the cleanest and greenest City in the region.”

“We met our commitments, delivering a turn-key multi-unit fuel cell park on schedule and in less than a year,” said Chip Bottone, President & Chief Executive Officer, FuelCell Energy, Inc. “Our team developed the project, manufactured the fuel cell power plants, performed engineering, procurement and construction services, and now that the plants are operational, FuelCell Energy will operate and maintain the fuel cell park for Dominion during the 15 year term of the energy purchase agreement.”

For more information, visit www.fuelcellenergy.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Flotek Industries (FTK) is a Growing Small-Cap Company with Prudent Management

Flotek Industries is a company that experienced phenomenal growth starting in mid-summer. From the beginning of July until the first week of October when the company peaked, the value of the stock increased by more than 34%. Since that time, the stock has been on a well-defined bearish trend, but it looks like it has reached an important support line at $19.05.

This company may be a good long-term investment and the timing might be right to look at it. This is a company that provides the chemicals to the oil and gas industry that does vertical and horizontal drilling. One of the reasons I encourage investors to look at this company is because it has “renewable revenue” since oil and gas exploratory companies will continually buy their products. This represents a healthy revenue source.

I know the company has been in a bearish trend, but it mirrors (on a lagging basis) the price of oil and gas. This is understandable since its clients are also influenced by the price of oil and gas. The United States Oil Fund (USO) peaked at the beginning of September, a month before FTK did, and it also defined its bottom before it started to turn up at the beginning of November, also a month before Flotek.

Let’s take a look at the company’s third-quarter numbers; even though the value of the stock continued to move down through most of the quarter.

Third Quarter
The company had a strong third quarter, with revenue of approximately $98.4 million compared to a year ago when it was only at $78.6 million. Year-over-year, Flotek generated a revenue increase of $19.8 million, but I must point out that the main bulk of the growth came from an acquisition. When it purchased Florida Chemical Company, the purchase added revenues of $18.6 million during the third quarter.

Accounts receivable also increased to $62.6 million from $44 million a year ago for the same reason as revenue growth.

A quick look at the company’s divisions will indicate that Energy Chemical Technologies is by far the most productive segment:

• Energy Chemical Technologies – $51.7 million with gross margins of 42.3%
• Consumer & Industrial Chemicals Technologies – $15.3 million with gross margins of 23.5%
• Drilling Technologies – $27.6 million with gross margins of 39.3%
• Artificial List Technologies – $3.9 million

The Drilling division is being challenged by the reduction in well fracking due to multi-well pad technology.

In a recent article written on Halliburton (HAL), the development of multi-well pads was mentioned. These new “pads” reduced traffic and made drilling more efficient so that not as much service and equipment was in demand. The following is a quote from the article: “With the development of horizontal drilling, came the creation of multi-well pads. Vertical wells require a separate pad for each well but horizontal drilling allows for multi-wells on one pad. This is made drilling much more efficient because once wells drilled a rig may only have to move 20 feet or so to drill the next one which also reduces truck traffic.”

Solid Company with Solid Ratios
For a small-cap company, Flotek has performed well and consistently leads its industry. One of the most important factors considered for an investor is sales performance. Over the last five years, its sales have increased by 14.64%. This is more than 60% above the industry average.
A company that has growing revenue, can manage its finances well, is performing well and has low debt should definitely be watched. Flotek seems to have all these going for it.

• Its gross margins are at 40.07%, well above the industry average of 26.80%.
• It has very low debt compared to the industry with a debt/equity ratio of 0.17 while the industry floats well above it with an average debt/equity ratio of 0.75.

If that isn’t enough, Flotek management has also done a good job with “efficiency management.” Look at these income and revenue ratios as compared to the industry average:

• Income/Employee ($119,441.98) Industry ($51,329.10)
• Revenue/Employee ($856,590.12) Industry ($578,054.61)

As the company grows, it continues to develop its infrastructure to support its oilfield portfolio. These are the projects that Flotek is currently working on:

• Completion of production, storage and transportation enhancement to the company’s primary chemistry production facility in Marlow, Oklahoma
• The construction and development of a state-of-the-art technology facility for Teledrift, Cavo motors and Flotek’s other drilling technologies in Moore, Oklahoma
• Construction of a new facility to house the company’s expanding operation in North Dakota’s Williston Basin
• Expansion of Florida Chemical’s storage capacity in Waller, Texas
• The development of expanded laboratory facilities in the Woodlands to support the combination of Flotek and Florida Chemical’s advanced chemistry research, production of new Stemulator tools and capital for expansions to meet growth in Commercial and Industrial Chemical Technologies facilities in Florida and in Enhanced Oil Recovery infrastructure

We have a company with a re-occurring and growing revenue base. It has minimal debt with a management team that has shown great efficiency in being able to use its resources and employees to generate income. As the exploration of oil and gas through fracking continues to grow; so should the size of the company and the value of the stock. This is a good value investment candidate.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Aethlon Medical, Inc. (AEMD) Video Chart for Friday, December 27, 2013

AEMD has put together a solid 2013, building an uptrending chart of steady higher lows. After consolidating from 52-week highs near 30 cents, the chart has rolled off a support at 13 cents and climbed back over the 50-day moving average and resistance at 15 cents. Technical traders will be looking for the new support to hold and for the chart to challenge resistance at 18 cents.

To view the video chart, visit the following link: http://www.missionir.com/videos.html

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Thursday, December 26, 2013

Big Tree Group, Inc. (BIGG) Setting Foundation for Growth in Burgeoning Regional Toy Markets

Over the years, China has emerged as the world’s largest manufacturer and exporter of toys, with over 20,000 toy production and distribution companies operating within its borders. One Chinese province in particular, the Guangdong province, is well-known globally for being the “toy capital of the world”, due to its extensive toy production and exporting activity.

Globally, the toy market was estimated to be $84.1 billion in 2012. One emerging toy industry-related company, Big Tree Group, is making its mark on this global marketplace by serving as an authorized sales agent for more than 8,000 toy manufacturers in China. The company functions as a “one-stop shop” for the sourcing and distribution of toys and related products, offering in excess of 300,000 kinds of toys including remote control toys, digital toys, and sports toys, play sets, educational toys, dolls, and infant toy products. It conducts these toy sourcing and distribution operations through two subsidiaries, Big Tree Brunei and Big Tree Shantou. The company also markets a proprietary construction toy, the Magic Puzzle (3D), which is currently available in Chinese domestic markets.

Headquartered in Shantou City of the Guangdong province, Big Tree Group features its toy product offerings in its 21,000+ square foot exhibition room as well as its online store.

Recently, Big Tree Group reported it had obtained a leasing agreement for a 4,000 square foot showroom in Bangkok Thailand. The company obtained the leasing space in an effort to expand into the ever-growing Southeast Asia toy market. While Southeast Asia remains the third largest toy market on the globe – it lags behind the toy markets in the United States and the European Union – it will reportedly become the largest traditional toys and game market worldwide sometime within this decade. In just Thailand alone, according to Euromonitor International in 2011 the country saw double-digit growth in toys and games sales, much of which was accounted for imported brands. The company is also seeking expanded distribution channels in emerging markets in South America as well.

With a strong assortment of toy and game offerings and an experienced management team, Big Tree Group looks to be setting a strong foundation for profitable growth in these key burgeoning regional markets as well as established ones.

For more information, visit www.bigtreegroup.net

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

First Titan Corp. (FTTN) Aligned to Profit from Rebound in U.S. Oil & Gas Production

The 50 largest U.S. oil and gas companies shelled out approximately $185 billion on domestic exploration and development efforts in 2012, an increase of 20 percent from the year prior. Industry behemoths are producing oil at an unprecedented rate, making the U.S. the fastest-growing oil and natural gas producer in the world.

Industry-wide potential prompted the International Energy Agency (IEA) to recall its previous forecasts that Saudi Arabia would hold its reign as the world’s top oil producer through 2035 – now forecasting that by 2017 the United States will take the rank of the world’s largest oil producer.

If this forecast comes to fruition, the United States would dramatically buck the trend of other importing countries, becoming all but self-sufficient in net terms. The rebound in U.S. oil and gas production is driven by upstream technologies with the ability to access once untouchable tight oil and shale gas resources.

One such company utilizing cutting-edge technology to extract oil and gas resources is small-cap oil and gas exploration and development company First Titan Energy. The company’s efforts are focused on recovering fossil fuels that were once considered too difficult or too expensive to recover. New innovations in drilling, combined with rising global demand and cheaper gas and electricity prices, has positioned the company as a premier early-stage company with strong growth potential.

The company’s current focus is on the exploration and development of oil and natural gas resources in the southern region of the United States. First Titan maintains drilling activities at its acquisition in South Lake Charles, Louisiana, and new acquisitions are to include five new wells along the Gulf Coast, from West Texas to Alabama.

Alert to the burgeoning growth of the oil and gas industry, First Titan continuously seeks partnerships with energy developers that are pursuing innovative new methods of oil and gas extraction, including the development of new technologies, cleaner methods, and unconventional resources.

For more information, visit www.firsttitanenergy.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

American Restaurant Concepts, Inc. (ANPZ) Issues Year in Review Letter to Shareholders

With the end of the year right around the corner, many companies are taking the time to reflect back on this year’s accomplishments. American Restaurant Concepts, owner and franchisor of Dick’s Wings & Grills restaurants, is one such company.

American Restaurant’s CEO, Richard Akam, issued a letter to shareholders detailing the company’s year in review. The text of the letter is as follows:

To our stockholders,

I would like to take this opportunity to express my appreciation to you for all of the support you have provided to the company and its management team this past year, and for the patience you have displayed as long-term investors. We are grateful for the continued confidence of everyone who owns a share in our company.

This past year marked a pivotal and exciting time for American Restaurant Concepts. During this period, we began the process of transforming the company from a Jacksonville, Florida-based franchisor of Dicks Wings® restaurants into a national franchisor of a diversified mix of premium restaurant brands.

Let me briefly recap the several noteworthy achievements and organizational changes that were made to enhance the long-term profitability of American Restaurant Concepts this past year:

• We substantially increased our royalty revenue, average royalty per active restaurant and franchisee profitability.
• We paid off virtually all of our outstanding debt.
• I was honored to be appointed CEO, joining Daniel Slone as our new CFO and Ketan Pandya as a member of the board of directors.
• We appointed key personnel into the positions of Director of Operations, Director of Training and Quality Assurance, and Director of Business Development.
• We introduced a new Dick’s Wings & Grill logo and a new “Family Fun Foodery” tag line to our brand.
• We entered into a sponsorship agreement with the Jacksonville Jaguars that provided us with the right to operate a Dick’s Wings & Grill concession stand at EverBank Field.
• We completed a 1-for-7 reverse stock split of our common stock to make our stock more attractive to institutional investors and strategic partners.
• We obtained a $1 million revolving line of credit facility from Blue Victory Holdings, a Louisiana-based private equity firm.
• We opened a new Dick’s Wings restaurant in the Nocatee development in Ponte Vedra, FL.
• We engaged Upside Group Franchise Consulting to help us design and implement a comprehensive branding platform to accelerate our franchise sales efforts.

We are already blessed with several attributes that most companies spend a lifetime trying to attain: a strong brand, best-in-class products, compelling long-term opportunities, focused strategies, and an incredibly capable and energized team. We have a 100% franchised, asset-light business model with high margins and low capital expenditure requirements that will result in strong future cash flow generation. We also have an intense focus on driving franchise profitability, which will drive strong returns for both our franchisees and stockholders.

Our entire management team has worked tirelessly to further develop our Dick’s Wings franchise, establish new relationships and identify new industry opportunities. Of course, our efforts would be fruitless without the dedication of our franchise partners who bring passion to their jobs and who delight in sharing our signature chicken wings with customers. I appreciate their continued efforts and could not be more grateful for what they have achieved this past year.

We believe our future is brighter than it has ever been. We are performing exceptionally well and believe we are making the right investments in the people, assets and companies to allow us to grow quickly and efficiently during 2014. When I reflect upon how far we’ve come during the past year, I could not be more motivated and optimistic about what we will achieve in the next year.

I know that great things lie ahead for American Restaurant Concepts. I am very proud to lead this company and will aspire to do what’s right for our company and our stockholders.

On behalf of our entire team, we thank you for believing in us, our company, our brand, our products and our future, and for your continued support of, and confidence in, American Restaurant Concepts.

As 2014 quickly approaches, American Restaurant Concepts is sure to continue the path of success it has forged and built upon throughout the past year. Its award-winning Dick’s Wings & Grill restaurant concept continues providing customers with tasty, fresh cuisine under American Restaurant Concept’s professional guidance. For more information on the company and its award-winning concepts, please visit www.dickswingsandgrill.com.

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

The Aristocrat Group Corp. (ASCC) RWG Handcrafted Vodka Earns an Ultra-Premium Label

Established in 2013, RWB Ultra-Premium Handcrafted Vodka is born of the idea that a brilliant spirit should be judged on the quality of its craftsmanship.

Using only the finest ingredients from America’s Heartland, RWB Vodka is a spirit of unparalleled clarity, cleanliness, and finish that offers a superior taste. As a result of this consistent level of quality, RWB has earned the label of an Ultra-Premium brand.

Since there are no federal or state guidelines on the use of “premium” descriptive terms, this particular designation is appropriated based on how the spirit feels on the palette. When tasting vodkas, there are four attributes to consider: 1) a tinge on the front of the tongue, 2) a lasting burn down the back of the throat, 3) how it feels in the back of the mouth, or, “gills”, and 4) overall flavor.

The best vodkas will leave no tinge or burn, will feel smooth in the “gills” and finally, will have an overall sweet and smooth flavor that makes them delicious.

RWG Ultra-Premium Handcrafted Vodka is a potato-based, 100% gluten-free spirit that obtains its uncompromising taste and finish from a unique, four-column distilling process, exceptional water from a 200 foot-deep well that taps into the Snake River Aquifer, and a five-stage filtration system.

For vodka in particular, some filtrations are not only necessary, but for quality control purposes, they are required. Charcoal filtration adds a clarity, crispness, and sparkle to the blended alcohol and water combination, which is vodka.

The pure and supreme taste of RWB Ultra-Premium Handcrafted Vodka matched with quality, fresh ingredients serves as the premise to making any cocktail and occasion simply perfect.
For more information about RWB Vodka, or to learn how to partake at tasting events, red carpet premieres, exclusive galas and the most anticipated concert events, visit the website at www.RWBVodka.com.

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Nexus Enterprise Solutions, Inc. (NXES) is Dedicated to Lead Quality

Nexus Enterprise Solutions is committed to the highest quality standards in lead generation data. And when it comes to auto and life insurance leads, Nexus operations and technologies are built entirely around quality control.

With dozens of years of collective experience in lead generation and online marketing technologies, Nexus has the expertise to convert traffic into sales. Providing far more than new prospects, they are a quality control enforcer who ensures their nationally branded clients receive superior customer data that actually produces product sales.

Because they specialize in quality, precision, and efficiency with their lead generation, Nexus’s integrity and success depends on maintaining these standards of excellence. So what exactly is lead quality?

Quality means that Nexus does not buy or sell any incentive-based, co-registration, or SMS/text-generated leads. And they have multiple fraud detection checks in order to verify customer identity and determine exclusivity. This practice protects their buyers, as well as the buyers’ consumers.

Using a multitude of different lead sources, from Pay-Per-Click and Email to SEO and Banners, Nexus Enterprise Solutions is setting new standards of quality and innovation for B2B big data management, while maintaining their focus on the lead generation marketplace.

Some time ago, Nexus correctly assessed that having the intermediary technology to properly track and allocate leads with a full suite of data-analysis tools would be required to survive the consolidation of the lead generation industry. Now, they are now poised to capitalize on the smaller players being forced out of the marketplace, and remain one of the last companies standing in an industry with explosive ongoing growth.

For more information, visit the website at www.nexusenterprisesolutions.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

CytRx Corp. (CYTR) Featured in Bullish Seeking Alpha Article

CytRx, a biopharm research and development company specializing in the development of drug candidates for the field of oncology, was recently covered in an article by Seeking Alpha contributor U.S. Biotech Investor, who reviews data from the company’s recent phase 2b clinical trial data before issuing a bullish stance on the company’s stock.

To read the entire article visit http://seekingalpha.com/instablog/15280302-u-s-biotech-investor/2523681-cytrx-corporations-aldoxorubicin-looks-like-a-winner

Aldoxorubicin is an improved formulation of doxorubicin, a widely used but highly toxic chemotherapy agent. CytRx recently released interim clinical data from a phase 2b trial in which aldoxorubicin demonstrated superiority to doxorubicin as first-line treatment of soft tissue sarcomas (STS). Results showed that patients administered aldoxorubicin were able to tolerate 3.5 times the standard dose of doxorubicin with fewer side effects, resulting in greater positive response to treatment.

“If trials continue as successfully as they have, Investors should see aldoxorubicin take the place of doxorubicin. CytRx Corporation will also find an immediate market with a monstrous revenue stream,” writes U.S. Biotech Investor.

The article also recaps words from CytRx CEO Steven Kriegsman, who is quoted as saying that aldoxorubicin’s underlying linker technology “has broad potential utility with proven affinity to couple with multiple chemotherapeutic agents including paclitaxel, docetaxel, cisplatin, irinotecan and methotrexate. Each of these agents may be incorporated into our future clinical development plans.”

A brief summary of CytRx precedes the author’s conclusion that:

“CytRx Corporation shares are in the start of a per share revaluation. The reset forming is due to solid data released on a coming best in class cancer treatment targeting soft-tissue sarcoma. The recent profit taking that occurred after favorable data release spiked the share price has created an attractive entry point. The savvy investor is now buying a position in Cytrx having had the patience to wait out profit taking.”

For more information visit www.cytrx.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Monday, December 23, 2013

MeetMe, Inc. (MEET) Mobile Ad Inventory Smoothly Transitioned to Pinsight Media+ Platform, Major Boon for 2014 CPM Rates

MeetMe, which has established a massive social discovery presence through ingenious use of gaming and highly engaging apps that help people make new friends and meet, reported seamless transition of their mobile ad inventory to the Pinsight Media+™ platform today, with content delivery already underway.

This initiative represents brilliant execution of the company’s ramp into tighter advertising rates for 2014, with premium cost per impression (CPM) metrics captured as a result of the smooth integration with Pinsight (Sprint’s mobile advertising division), whose audience targeting technology reaches deep into a set comprised of millions of mobile user’s first-party data. This implementation of the contract signed back in November with Pinsight, to sell substantially all of MEET’s inventory on the platform, fuses the company’s uniquely powerful market dynamics with Pinsight’s enormous network scale and publishing flexibility, taking full advantage of MeetMe’s attractive user demographics and the performance strength of their ad units.

CEO of MEET, Geoff Cook, anticipating “significantly better” mobile ad rates on average in 2014 as a result of this agreement, explained that a projected 15%-plus jump in mobile CPM over what the company pulled down in Q4 this year forms the basis of a strong foundation for MEET’s long-term growth strategy. Cook cited an incremental $4.1M in mobile revenue over the course of 2013 could have been obtained if this agreement had been in place, clearly showcasing the fact that over half their mobile app users are already exposed to the platform and that their characteristics are bullish for rapid adoptance, with exposure projected at 100% within the next few weeks.

The strength of that user base has been a huge key to MEET’s success and the company’s proficiency at cultivating mobile-driven communities is apparent, as 60% or more of their traffic is attributable to mobile users, with deployment hitting every major mobile platform, either via the site or platform-specific apps in multiple languages. With guaranteed CPM rates through 2014 via the agreement, MEET is now primed for explosive growth.

CRO of MEET, Bill Alena, echoed Cook’s sentiments and went on to explain that the vast ad impression space Pinsight manages, with billions of impressions spanning an entire digital landscape of owned/operated properties, grants the company optimum targeting impact. With powerful tools like behavioral and interest graph targeting driven by a huge database of raw location and demographic data, MEET will now be serving ads in a far more focused way than ever before.

More info on MeetMe, Inc. is available at www.MeetMeCorp.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

MIND C.T.I. Ltd. (MNDO) Announces Two New Significant Wins

MIND C.T.I. Ltd., a prominent supplier of convergent end-to-end billing and customer care product based solutions for service providers as well as call accounting solutions, announced today that the company has recently won two significant deals, one at the start of the quarter and the other closed last week.

The first sizeable win is a deal to support prepaid and postpaid wireless business for a wireless communications service provider in the US. Specifically, MIND will implement its convergent billing and customer care platform. The solution includes modules such as Point of Sales (PoS), Self-care, Online Store, Interactive Voice Response (IVR), and support for Verizon Wireless LTE in Rural America (LRA Program).

MIND was chosen by this customer for its flexibility and support with constant changes necessitated by carrier marketing activities, its broad range of functionalities for prepaid plans, its collections business process and promotions features, and finally for MIND’s proven true convergence. That convergence is the output of one integrated platform, with all modules built in, which fully supports all prepaid, postpaid, hybrid, and wholesale business models. Implementation of this project has already begun and will be completed within the next three to four quarters.

This win is a testament to MIND’s strengthening presence in the US market, the swelling reputation of MIND’s cutting edge solutions, and reputation of on-time successful implementations.

The second win is with an existing customer in East Europe, a carrier with over 1.5 million subscribers that operates in all telecom fields, landline, wireless, broadband and TV, and uses MIND’s solution for part of their business. Over the next two years this customer will phase out other platforms they use and upgrade the MIND solution to reach the true real-time convergent platform they desire in order to attract and retain their customer base. MIND was chosen after an extremely long and thorough search. This significant win is a multi-million dollar deal and the company expects to recognize its revenue during a phased implementation within the next eight to ten quarters.

“We are pleased to announce these two new important wins. For the last few years we have focused on preparing the company for such potential wins. We have maintained a global presence and have increased our workforce to enable support of these larger prospects in our pipeline as they turn into new projects. These latest wins show how MIND’s solutions are gaining market share”, said Monica Iancu, President and CEO of MIND CTI. “We continue to experience increased interest in our solutions and we expect to meet our goal of internal growth.”

For further information, please visit www.mindcti.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Ultralife Corp. (ULBI) Signs $6.7M Medical Cart Contract with Scott-Clark Medical

Ultralife, a global provider of products and services ranging from portable power solutions to communications and electronics systems for government, defense, and commercial customers, says it has received final IEC certification for its newly developed medical cart battery and intelligent power supply system, and has expanded its strategic supplier agreement with medical cart provider, Scott-Clark Medical.

Per the agreement, Scott-Clark Medical is integrating Ultralife’s battery and intelligent power supply system with its own medical carts for sales to hospitals and other medical institutions worldwide, and plans on marketing Ultralife’s battery and intelligent power supply system to other medical cart OEMs. The expanded agreement allows for shipments until September 2016 and increases the initial contract value to $6.7 million from approximately $1.6 million. Ultralife expects to commence initial shipments later this month.

As evidence of its growing market reach, Scott-Clark Medical recently signed a multi-year contract with a tier-one medical cart OEM that specializes in upgrading existing units in the field. Shipments under this contract are expected to begin in early 2014.

“Over the past 18 months, our new products engineering team has been collaborating with the Scott-Clark team to develop a first-class flexible solution with continuous mobile power to serve both new production and retrofit opportunities in the medical cart industry. With their industry knowledge and market access, Scott-Clark is an ideal partner to help us quickly penetrate the market and realize these exciting new business opportunities,” Michael D. Popielec, Ultralife’s president and CEO stated in the press release. “This technically advanced application of our multi-kilowatt module platform is a clear demonstration of our strategy to leverage the proven military-grade reliability of our batteries and chargers to diversify our business into commercial markets. We look forward to the revenue growth opportunities the new medical cart products and business partner relationship will provide.”

Richard Flynn, president of Scott-Clark Medical, emphasized the value of Ultralife’s solutions in an increasingly high-demand market.

“Ultralife’s engineering, design, and test capability coupled with their reputation as a leader in the development of advanced battery technology solutions for demanding applications led us to partner with the company to enhance the initial power design we came to them with for our medical carts,” Flynn stated. “Based on the very positive feedback we received from customers who tested prototypes, we decided to expand our relationship with Ultralife and we are confident that the medical cart customers will embrace this new power supply technology. Ultralife is proving to be a great choice for us to best serve this growing market.”

For more information, visit www.ultralifecorp.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Synta Pharmaceuticals Corp. (SNTA) Adds Steven Bernitz as New Senior Vice President, Corporate Development

Synta Pharmaceuticals announced earlier today the recruitment of Steven Bernitz to the position of Senior Vice President, Corporate Development. Bernitz brings with him over 20 years of experience in corporate strategy, business leadership and transactional experience in life sciences.

Prior to Synta, Bernitz was a General Partner and Head of the BioPharma Practice at Extera Partners, a business development advisory firm. While at Extera, Bernitz directed a number of business development and strategy initiatives for development stage companies and their investors in areas such as autoimmune, oncology, and orphan diseases.

Before joining Extera in 2010, Bernitz held the role of Chief Business Officer at Concert Pharmaceuticals where he oversaw Concert’s $1 billion deal with GlaxoSmithKline. Prior to Concert he sat as Senior Vice President, Business and Product Development at Coley Pharmaceutical Group, where he led a plethora of transactions including Coley’s $600 million oncology deal with Pfizer. In addition, Bernitz’s experience includes acting as CEO of Histogenics and Organogenesis, both cell therapy companies, and before that he was with Merck Vaccines and McKinsey & Co.

“Steve has tremendous deal experience, as is clear from his track record, which will be valuable in realizing the potential of both our ganetespib and HDC programs,” stated Safi Bahcall, President and CEO, Synta. “His wealth of diverse business experiences and insights make him an excellent addition to our executive team, as we manage a growing pipeline and an increasing number of important strategic and operational choices.”

“Synta has the potential to make a tremendous difference in the lives of cancer patients,” commented Bernitz. “Both ganetespib and the HDC platform represent innovative new treatment approaches that can transform standard of care. I am excited to join the team and help achieve these ambitious goals.”

Bernitz holds an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University, where he was an Austin Scholar. His B.S. summa cum laude is from Tufts University, where he was elected to Phi Beta Kappa.

For more information, please visit www.syntapharma.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com


Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

OxySure Systems, Inc. (OXYS) Gaining Global Marketplace Traction

OxySure Systems is a Texas-based medical technology company that designs, manufactures, and distributes specialty respiratory and medical solutions. The company is the creator of a groundbreaking medical technology that allows oxygen to be delivered on demand, via the instantaneous creation of medically pure oxygen from two dry, inert powders. Since the product is revolutionary, is easy to operate, does not require specialized care or maintenance, and has potential to become a mainstream medical device, it is already gaining traction in the global medical device marketplace.

OxySure Systems’ launch product, the OxySure Model 615, uses this technology to enable parents, passersby, or even victims to administer oxygen when it is needed in a medical emergency. The machine model is already an FDA-cleared model that has been installed and used in multiple facilities across the United States. A user only has to turn a knob, and the OxySure Model 615 is ready for instant use. The product is already gaining the attention of many inside and outside the medical technology industry, having received numerous accolades such as the Tech Titans Innovation Award in 2008 and MedVentures Award in 2011. It does not require a prescription for over-the-counter sale, either.

The global market potential for the OxySure Model 615 has been put at over 500 million units, with locations such as school campuses, manufacturing facilities, churches, and restaurants being mentioned as prospective places for product placement and installation. OxySure Systems has also been investigating the viability of the OxySure Model 615 being placed in more unique locations such as recreational vehicles. With the strong potential to become used as a mainstream medical device, the machine model may become as standard a medical unit in these locations as the fire extinguisher or the automated external defibrillator. End markets for the OxySure Model 615 in the United States alone could edge into the installment of over 100 million machine model units.
OxySure Systems has created a recurring revenue model with this machine model, as it possesses reusable hosing and a replaceable cartridge that must be replaced after each use or the end of a two-year shelf life. As more units are introduced into more global locations, this can turn into a stronger recurring revenues model. Additionally, the company’s oxygen creation technology gives it the capacity for other vertical markets as well.

Currently, OxySure Systems is seeking to further its product’s global presence through the establishment and leveraging of key partnerships with global distributors and large original equipment manufacturers worldwide.

This month has been a busy one for OxySure Systems. It just finished exhibiting at the world’s largest medical device tradeshow, the Medica 2013 Trade Fair. Taking place over four days, the convention reportedly attracted around 130,000 attendees a day. OxySure Systems subsequently received many inquiries about and distributor interest in its oxygen-providing technology. The company also solidified partnership deals with distributors in Hong Kong, Macau, and Chile. There is room for further distributive deals from the conference as well.

During Q3 2013, the company reported sales had jumped 428 percent. An early-December Wall Street Cheat Sheet article noted OxySure Systems as being an emerging attractive investment opportunity in the evolving marketplace of healthcare. Since it is an over-the-counter product, the OxySure Model 615 likely will not feature the medical device tax imposed by the Affordable Care Act.

With the OxySure Model 615 sporting groundbreaking oxygen-creating technology as its foundation and having potential to emerge as a mainstream medical device, OxySure Systems is on the road to gaining strong global marketplace growth.

For more information, visit: www.oxysure.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html